Nature Reviews Clinical Oncology - Table of Contents alert Volume 12 Issue 11

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
November 2015 Volume 12 Number 11
Impact Factor 14.180 *	In this issue Research Highlights News and Views Reviews Perspectives Also this month  Featured article: Clinical overview of metronomic chemotherapy in breast cancer Elisabetta Munzone & Marco Colleoni
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Primers in your inbox Nature Reviews Disease Primers launched in April 2015 and publishes Primers — introductory review articles that provide overviews of diseases and disorders. Primer articles describe all aspects of a condition: epidemiology; disease mechanisms; diagnosis, screening and prevention; management; and quality of life.  Stay updated on the latest Primers published.
Advertisement
The Naturejobs Career Expo is coming to Düsseldorf for the first time on 26 November! This career fair offers young, talented researchers an excellent opportunity to meet a diverse selection of national and international employers from academic institutions and scientific industries. The event is free and offers you a chance to meet and network with employers and leading scientific institutions and attend useful workshops.  Register and find out more.
RESEARCH HIGHLIGHTS Top Kidney cancer: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival Published online: 13 October 2015 p621 | doi:10.1038/nrclinonc.2015.178 PDF Immunotherapy: Evading immune escape: synergy of COX and immune-checkpoint inhibitors Published online: 22 September 2015 p622 | doi:10.1038/nrclinonc.2015.167 PDF Haematological cancer: PROLONGing PFS with ofatumumab in patients with CLL Published online: 29 September 2015 p622 | doi:10.1038/nrclinonc.2015.172 PDF Prostate cancer: AS—contemplation, not intervention Published online: 15 September 2015 p623 | doi:10.1038/nrclinonc.2015.160 PDF Prevention: Washing out oral mucositis Published online: 22 September 2015 p624 | doi:10.1038/nrclinonc.2015.158 PDF Breast cancer: Tracking ctDNA to evaluate relapse risk Published online: 15 September 2015 p624 | doi:10.1038/nrclinonc.2015.159 PDF Haematological cancer: Repositioned to attack CML cells Published online: 22 September 2015 p624 | doi:10.1038/nrclinonc.2015.166 PDF IN BRIEF Haematological cancer: A novel risk-classification tool for multiple myeloma | CNS cancer: MRI—a new approach to identify glioblastoma subtypes | Pancreatic cancer: Including the stromal compartment in PDAC classification PDF Clinical Oncology JOBS of the week Postdoctoral Fellowship � Department of Oncology St. Jude Children's Research Hospital (SJCRH) Postdoctoral Fellow Translational Oncology Helmholtz Association Senior group leader position in oncology research Cancer Research Centre of Lyon (CRCL) Doctoral candidate Helmholtz Association Marie Curie 15 PhD Fellowships University of Cambridge More Science jobs from Clinical Oncology EVENT More science events from
NEWS AND VIEWS		Top
Immunotherapy: Anti-PD-1 therapies—a new first-line option in advanced melanoma Ryan J. Sullivan & Keith T. Flaherty Published online: 29 September 2015 p625 | doi:10.1038/nrclinonc.2015.170 Treatment with pembrolizumab, an anti-PD-1 antibody, improved progression-free survival compared with investigator-choice chemotherapy in a phase II trial in patients with advanced-stage melanoma previously treated with ipilimumab. Two subsequent independent trials have confirmed that anti-PD-1 therapy is a better option than either chemotherapy or ipilimumab in the frontline setting. Full Text | PDF
Clinical trials: Early phase clinical trials—are dose expansion cohorts needed? Alexia Iasonos & John O'Quigley Published online: 06 October 2015 p626 | doi:10.1038/nrclinonc.2015.174 Dose-expansion cohorts (DECs) enable investigators to identify potentially effective drugs, for specific patient populations, in a single trial by assessing antitumour activity as early as possible. We discuss how the objectives, design and interpretation of DEC have evolved, and how DECs are changing the landscape of early drug development. Full Text | PDF
Chemotherapy: Limited use of the intraperitoneal route for ovarian cancer—why? Maurie Markman Published online: 13 October 2015 p628 | doi:10.1038/nrclinonc.2015.177 A recent objective study has demonstrated that the use of adjuvant platinum-based intraperitoneal chemotherapy in patients with small-volume residual advanced-stage ovarian cancer remains limited, despite the publication of several phase III trials demonstrating superior overall survival associated with this approach. Several factors might explain this far less than satisfactory state of affairs. Full Text | PDF
REVIEWS		Top
Clinical overview of metronomic chemotherapy in breast cancer Elisabetta Munzone & Marco Colleoni Published online: 04 August 2015 p631 | doi:10.1038/nrclinonc.2015.131 Metronomic chemotherapy has shown promising efficacy and minimal toxicity in patients with advanced-stage breast cancer. Moreover, the low cost of this regimen represents an opportunity for its expanded utilization, especially in developing countries. In this Review, the authors discuss the key clinical advances, including new trial design, appropriate patient and end point selection, and the evolving rationale for metronomic chemotherapy combinations. Abstract | Full Text | PDF
Surgical treatment of nonpalpable primary invasive and in situ breast cancer Muneer Ahmed, Isabel T. Rubio, Joost M. Klaase & Michael Douek Published online: 29 September 2015 p645 | doi:10.1038/nrclinonc.2015.161 Currently, more than a third of all breast cancers are nonpalpable at diagnosis, and this proportion is expected to increase owing to the expansion of effective breast-screening programmes. Surgical excision combined with axillary staging is the standard of care for patients with nonpalpable breast cancers, and requires accurate localization of the primary tumour prior to resection. This Review provides an overview of the various techniques available for the localization and surgical management of nonpalpable breast cancer, their advantages and disadvantages, and future directions for the development of new technologies. Abstract | Full Text | PDF
Lung cancer—a fractal viewpoint Frances E. Lennon, Gianguido C. Cianci, Nicole A. Cipriani, Thomas A. Hensing, Hannah J. Zhang, Chin-Tu Chen, Septimiu D. Murgu, Everett E. Vokes, Michael W. Vannier & Ravi Salgia Published online: 14 July 2015 p664 | doi:10.1038/nrclinonc.2015.108 The use of traditional Euclidean geometry can present challenges for analysis of image characteristics, particular those of extremely complex biological structures, obtained by medical and scientific imaging modalities. Fractal geometry is a potentially complementary mathematical approach that enables efficient estimation of geometrical complexity, and the irregularity of shapes and patterns. This Review introduces the concept of fractals and fractal geometry, and describes how analysis of fractal (non-integer) dimension and associated measurements, such as lacunarity (texture), can be performed and applied to the analysis of cancer. The authors discuss how fractal analysis might provide information on many diverse biological structures relevant to the natural history of lung cancer, which might prove useful for the diagnosis and management of this disease. Abstract | Full Text | PDF | Supplementary information
PERSPECTIVES		Top
OPINION Does surgery have a role in managing incurable gastric cancer? Sri G. Thrumurthy, M. Asif Chaudry, Ian Chau & William Allum Published online: 11 August 2015 p676 | doi:10.1038/nrclinonc.2015.132 Stage IV gastric cancer is incurable and has a very poor prognosis. Although palliative chemotherapy remains the standard of care, increasing evidence indicates that palliative surgery can provide a prognostic and symptomatic benefit. This Perspectives summarizes the recent evidence underpinning the medical and surgical management of incurable gastric cancer, and provides evidence-based recommendations on treatment strategies and avenues for future research. Abstract | Full Text | PDF
Advertisement
Signal Transduction and Targeted Therapy is a fully open access international journal devoted to publishing original research results and reviews on all aspects of signal transduction and targeted therapy. Now open for submission
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2015. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.